Abstract
IntroductionBenralizumab is an anti-IL5R monoclonal antibody licensed for patients with severe eosinophilic asthma (SEA). Phase 3 clinical trials demonstrated significant reductions in exacerbation rates and in maintenance oral corticosteroid (mOCS)...
Paper version not known (
Free)
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have